Condition: Lung Cancer · Sponsor: Royal Marsden NHS Foundation Trust
NIMBLE is a prospective study for blood biomarker study of lung nodules alongside analysing data which has been collected routinely as part of patient care. The primary aim of NIMBLE is to assess whether artificial intelligence and machine learning based radiomics approaches can be used to distinguish between benign disease and malignancy in a new lung nodule after a previously treated cancer, and where malignant to differentiate between metastatic recurrence or a new primary lung cancer.
This description comes directly from the study's public registry record.
Sejal Jain · 02078082603 · sejal.jain@rmh.nhs.uk
Laura Boddy · 02078082603 · laura.boddy@rmh.nhs.uk
Always discuss trial participation with your own doctor first.
| Barking Havering and Redbridge University Hospitals NHS Trust | Goodmayes, Essex, United Kingdom | Recruiting |
| Calderdale and Huddersfield NHS Foundation Trust | Huddersfield, United Kingdom | Recruiting |
| Princess Alexandra Hospital | London, United Kingdom | Recruiting |
| Whittington Health NHS Trust | London, United Kingdom | Recruiting |
| University College London Hospitals NHS Foundation Trust | London, United Kingdom | Recruiting |
| Guy's and St Thomas' NHS Foundation Trust | London, United Kingdom | Recruiting |
| Royal Marsden Hospital | London, United Kingdom | Recruiting |
| Northumbria NHS Foundation Trust | Newcastle upon Tyne, United Kingdom | Recruiting |
| Nottinghamshire Healthcare NHS Foundation Trust | Nottingham, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05432739